FDA Approves First Prescription Digital Treatment For Depression

‘Rejoyn’ is a smartphone app intended for use alongside antidepressant medications for people 22 and older who have a diagnosis of major depressive disorder.

It uses a six-week program that combines a new approach dubbed “cognitive-emotional training” and “cognitive behavioral therapy lessons.”

The treatment made by Otsuka Pharmaceutical and Click Therapeutics was cleared by the FDA based on results from a clinical trial.

Leave a Comment